UBS Group AG Boosts Holdings in Perspective Therapeutics, Inc. $CATX

UBS Group AG grew its position in shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) by 44.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 926,331 shares of the company’s stock after purchasing an additional 285,188 shares during the period. UBS Group AG’s holdings in Perspective Therapeutics were worth $2,547,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Russell Investments Group Ltd. raised its stake in shares of Perspective Therapeutics by 184.1% during the third quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock valued at $29,000 after purchasing an additional 5,475 shares during the period. SG Americas Securities LLC purchased a new stake in shares of Perspective Therapeutics during the third quarter valued at approximately $46,000. Mercer Global Advisors Inc. ADV raised its stake in shares of Perspective Therapeutics by 81.8% during the third quarter. Mercer Global Advisors Inc. ADV now owns 29,275 shares of the company’s stock valued at $100,000 after purchasing an additional 13,168 shares during the period. Auctus Advisors LLC purchased a new stake in shares of Perspective Therapeutics during the fourth quarter valued at approximately $87,000. Finally, Sherbrooke Park Advisers LLC purchased a new stake in shares of Perspective Therapeutics during the third quarter valued at approximately $111,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Analyst Ratings Changes

CATX has been the topic of a number of analyst reports. Truist Financial set a $12.00 price objective on shares of Perspective Therapeutics in a research note on Tuesday, March 17th. B. Riley Financial raised their price target on shares of Perspective Therapeutics from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, March 18th. Piper Sandler initiated coverage on shares of Perspective Therapeutics in a research report on Thursday, February 19th. They set an “overweight” rating and a $16.00 price target for the company. Wedbush reissued an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a research report on Tuesday, May 5th. Finally, HC Wainwright raised their price target on shares of Perspective Therapeutics from $12.00 to $13.00 and gave the stock a “buy” rating in a research report on Monday, March 23rd. One equities research analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $12.63.

Perspective Therapeutics Price Performance

CATX stock opened at $4.16 on Wednesday. Perspective Therapeutics, Inc. has a twelve month low of $1.96 and a twelve month high of $6.16. The firm has a 50 day simple moving average of $4.21 and a 200-day simple moving average of $3.67.

Perspective Therapeutics (NYSEAMERICAN:CATX) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. Perspective Therapeutics had a negative net margin of 17,982.69% and a negative return on equity of 42.33%. The business had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.16 million. On average, equities analysts anticipate that Perspective Therapeutics, Inc. will post -1.14 earnings per share for the current fiscal year.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.